KPV

KPV is a naturally occurring C-terminal tripeptide fragment of alpha-melanocyte stimulating hormone (α-MSH) consisting of lysine-proline-valine. Despite lacking melanocortin receptor binding activity, KPV retains potent anti-inflammatory properties through alternative mechanisms including inhibition of NF-κB activation and modulation of inflammatory cytokine production. Research demonstrates KPV reduces inflammation without significant immunosuppression, making it attractive for chronic inflammatory conditions. Studies show efficacy in models of inflammatory bowel disease, colitis, and skin inflammation. The tripeptide may benefit wound healing through its anti-inflammatory effects and has shown protective properties in various tissue injury models. KPV crosses cellular membranes more readily than full-length α-MSH due to its small size. Research indicates potential applications for IBD, dermatological conditions, and systemic inflammatory states. The peptide is generally well-tolerated and can be administered through multiple routes including oral and topical. KPV represents a targeted approach to inflammation modulation without the side effects of broader immunosuppression.

All evidence is preclinical (mouse and cell models); no human trials, no clinical pharmacokinetics, and no approved formulation. Claims about skin/wound applications rely on alpha-MSH extrapolations rather than direct KPV human data.

Natural tripeptide (Lys-Pro-Val), the C-terminal fragment of alpha-MSH; taken up across intestinal epithelium via the PepT1 di/tripeptide transporter; reported to suppress inflammatory cytokine signaling. Research-stage only.